Home > Cytovance Biologics Salary

Cytovance Biologics Salary

  • 18
  • 89
  • 100
Cytovance Biologics average salary is $87,485, median salary is $87,485 with a salary range from $87,485 to $87,485.
Cytovance Biologics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Cytovance Biologics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 Cytovance Biologics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Relationship & Strategic Manager 87,485-87,485 Boca Raton, FL, 33427 2013 Cytovance Biologics Relationship & Strategic Manager Salaries (1)
Cytovance Biologics Boca Raton, FL Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Cytovance Biologics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Cytovance Biologics Jobs
See more Cytovance Biologics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Cytovance Biologics... Information
  • Cytovance Biologics Inc
  • Industry: BioTech/Drugs
  • City: Oklahoma, OK
  • Our mission is to be the definitive full service contract manufacturer for the production of clinical scale therapeutic proteins and antibodies for the biotech industry.The Cytovance team understands from first-hand experience the need for more options for comprehensive contract manufacturing services. While there is some debate about the size of the cell culture capacity shortage for commercial stage biopharmaceutical products, the adequacy of clinical capacity is an equally critical question, especially for development stage companies. The clinical manufacturing capacity that does exist is mostly controlled by larger therapeutics companies or commercial scale contractors that are often inaccessible to development stage